The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
Open accessAbstract
// Danlin Yao 1,2,* , Ling Xu 1,2,* , Jiaxiong Tan 1,2 , Yikai Zhang 1,2 , Shuai Lu 1 , Mingde Li 1,2 , Sichun Lu 1,2 , Lijian Yang 1 , Shaohua Chen 1 , Jie Chen 2 , Jing Lai 2 , Yuhong Lu 2 , Xiuli Wu 1,2 , Xianfeng Zha 3 and Yangqiu Li 1,2 1 Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, Jinan University, School of Medicine, Jinan University, Guangzhou, China 2 Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China 3 Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, China * These authors have contributed equally to this work Correspondence to: Yangqiu Li, email: // Keywords : memory T cells, TSCM, CML, TKI, Immunology and Microbiology Section, Immune response, Immunity Received : June 28, 2017 Accepted : August 27, 2017 Published : September 16, 2017 Abstract T cell immune surveillance is considered an important host protection process for inhibiting carcinogenesis. The full capacity of T cell immune surveillance is dependent on T cell homeostasis, particularly for central memory T (T CM ) cells and stem cell memory T (T SCM ) cells. In this study, distribution of T cell subsets in peripheral blood from 12 patients with chronic myeloid leukemia (CML) and 12 cases with CML in complete remission (CR) was analyzed using a multicolor flow cytometer, and 16 samples from healthy individuals (HIs) served as control. The proportion of CD8 + T SCM and CD4 + and CD8 + T CM cells were lower, while CD4 + effector memory T (T EM ) cells and CD4 + and CD8 + terminal effector T (T EF ) cells were higher in CML patients compared with HIs. Moreover, the proportion of CD8 + CD28 - T cells, which were found to have the immune suppressive function, increased in the naive T (T N ) cell and T CM subsets in CML patients compared with HIs. Our study reveals that elimination of leukemia cells by treating with tyrosine kinase inhibitors (TKIs) restores the memory T cell distribution from a skewed pattern in CML patients who are under leukemia burden, indicating that leukemia-specific immune responses mediated by T cells might be induced and maintained in CML patients, however, these responsive T cells might gradually become exhausted due to the continued existence of leukemia cells and their environment; therefore, T cell activation using a different approach remains a key point for enhancing global T cell immunity in CML patients, even for those with CR status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reconstructed and expanded CAR-T cells are exposed to the patient's tumor microenvironment, thereby inducing the senescent phenotype of CAR-T.
“The reconstructed and expanded CAR-T cells are exposed to the patient's tumor microenvironment, thereby inducing the senescent phenotype of CAR-T [122, 123].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C. A., Gambacorti-Passerini, C. B., Niederwieser, D. W., Resta, D. J., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,005
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Self-citationMemory T Cell Subsets, Migration Patterns, and Tissue Residence
Mueller, S. N., Gebhardt, T., Carbone, F., & Heath, W. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095954 · Cited by 884
Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4
Chang, C.-C., Ciubotariu, R., Manavalan, J. S., Yuan, J., Colovai, A. I., Piazza, F., Lederman, S. M., Colonna, M., Cortesini, R., Dalla‐Favera, R., et al. (2002) · Nature Immunology · doi:10.1038/ni760 · Cited by 803
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Nagaraj, S., Schrum, A. G., Cho, H.-I., Celis, E., & Gabrilovich, D. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902661 · Cited by 418
Apperley, J. F. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62120-0 · Cited by 398
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H., Schmid, C., Barrett, A. J., & Schendel, D. J. (2003) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 396
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle‐Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 322
Filaci, G., Fenoglio, D., Fravega, M., Ansaldo, G., Borgonovo, G., Traverso, P., Villaggio, B., Ferrera, A., Kunkl, A., Rizzi, M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4323 · Cited by 229
Lugli, E., Gattinoni, L., Roberto, A., Mavilio, D., Price, D. A., Restifo, N. P., & Roederer, M. (2012) · Nature Protocols · doi:10.1038/nprot.2012.143 · Cited by 209
Neoplastic Diseases of the Blood
Wiernik, P. H., Kyle, R. A., Dutcher, J. P., & Goldman, J. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2 · Cited by 176
Schnorfeil, F. M., Lichtenegger, F. S., Emmerig, K., Schlueter, M., Neitz, J. S., Draenert, R., Hiddemann, W., & Subklewe, M. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0189-2 · Cited by 152
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 139
Kondo, T., Morita, R., Okuzono, Y., Nakatsukasa, H., Sekiya, T., Chikuma, S., Shichita, T., Kanamori, M., Kubo, M., Koga, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15338 · Cited by 106
Corrado, C., Saieva, L., Raimondo, S., Santoro, A., Leo, G. D., & Alessandro, R. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12873 · Cited by 105
Bachireddy, P., Hainz, U., Rooney, M. S., Pozdnyakova, O., Aldridge, J., Zhang, W., Liao, X., Hodi, F. S., O'Connell, K. E., Haining, W. N., et al. (2013) · Blood · doi:10.1182/blood-2013-08-523001 · Cited by 97
Rohoň, P., Porkka, K., & Mustjoki, S. M. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01501.x · Cited by 90
Crucian, B. E., Dunne, P. B., Friedman, H. P., Ragsdale, R., Pross, S. H., & Widen, R. H. (1995) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.2.2.249-252.1995 · Cited by 86
CD28− and CD28lowCD8+ Regulatory T Cells: Of Mice and Men
Vuddamalay, Y., & van Meerwijk, J. P. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00031 · Cited by 70
Miyamoto, T., Fukuda, T., Nakashima, M., Henzan, T., Kusakabe, S., Kobayashi, N., Sugita, J., Mori, T., Kurokawa, M., & Mori, S.-I. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.02.012 · Cited by 57
The roles of stem cell memory T cells in hematological malignancies
Xu, L., Zhang, Y., Luo, G., & Li, Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0214-5 · Cited by 47
Self-citationMyeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
Giallongo, C., Parrinello, N. L., Brundo, M. V., Raccuia, S. A., Rosa, M. D., Cava, P. L., & Tibullo, D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00107 · Cited by 42
Barbon, C. M., DAVIES, J. K., Voskertchian, A., Kelner, R. H., Brennan, L., Nadler, L. M., & Guinan, E. C. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12575 · Cited by 27
Recent advances in T‐cell immunotherapy for haematological malignancies
Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 25
Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients
Zahran, A. M., Badrawy, H., & Ibrahim, A. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0615-9 · Cited by 23
Adoptive T-cell therapy for Leukemia
Garber, H. R., Mirza, A., Mittendorf, E. A., & Alatrash, G. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-25 · Cited by 21
Li, Y., Yang, L., Chen, S., Li, R., Zhang, Y., Lu, Y., & Luo, G. (2002) · PubMed · Cited by 20
Self-citationLi, Y., Yang, L., Chen, S., Zhang, Y., Zhang, X., & Luo, G. (2004) · PubMed · Cited by 17
Self-citationChandran, R., Hakki, M., & Spurgeo, S. (2012) · InTech eBooks · doi:10.5772/50193 · Cited by 15
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
Sander, F. E., Rydström, A., Bernson, E., Kiffin, R., Riise, R. E., Aurelius, J., Anderson, H., Brune, M. L., Foà, R., Hellstrand, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7210 · Cited by 15
Xu, L., Lu, Y., Lai, J., Yu, W., Zhang, Y., Jin, Z., Xu, Y., Chen, J., Zha, X., Chen, S., et al. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4930-4 · Cited by 13
Self-citationAn overview of chronic myeloid leukemia and its animal models
Ma, W.-X., Ma, N., Chen, X., Zhang, Y., & Zhang, W. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4965-6 · Cited by 10
Self-citationGeneration of V α13/β21+T cell specific target CML cells by TCR gene transfer
Zha, X., Xu, L., Chen, S., Yang, L., Zhang, Y., Lu, Y., Yu, Z. H., Li, B., Wu, X., Zheng, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12441 · Cited by 10
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510
Self-citationT cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 282
Self-citationAge related human T cell subset evolution and senescence
Li, M., Yao, D., Zeng, X., Kasakovski, D., Zhang, Y., Chen, S., Zha, X., Li, Y., & Xu, L. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0165-8 · Cited by 230
Self-citationTCR-T Immunotherapy: The Challenges and Solutions
Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.794183 · Cited by 116
Self-citationTan, J., Yu, Z. H., Huang, J., Chen, Y., Huang, S., Yao, D., Xu, L., Lu, Y., Chen, S., & Li, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0185-8 · Cited by 86
Self-citationCD38: an ecto-enzyme with functional diversity in T cells
Ghosh, A., Khanam, A., Ray, K., Mathur, P., Subramanian, A., Poonia, B., & Kottilil, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146791 · Cited by 40
Tan, J., Chen, S., Huang, J., Chen, Y., Yang, L., Wang, C., Zhong, J., Lu, Y., Wang, L., Zhu, K., et al. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13033 · Cited by 38
Self-citationAlmeida, J. S., Couceiro, P., López-Sejas, N., Alves, V., Růžičková, L., Tarazona, R., Solana, R., Freitas-Tavares, P., Santos-Rosa, M., & Rodrigues‐Santos, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02493 · Cited by 35
Xu, L., Yao, D., Tan, J., He, Z., Yu, Z. H., Chen, J., Luo, G., Wang, C., Zhou, F., Zha, X., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0636-y · Cited by 34
Self-citationImmune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
Hajifathali, A., Parkhideh, S., Kazemi, M. H., Chegeni, R., Roshandel, E., & Gholizadeh, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29769 · Cited by 26
Zhang, Y., Wang, N., Ding, M., Yang, Y., Wang, Z., Huang, L., Zhu, W., Mellor, A. L., Hou, X., Zhou, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01012 · Cited by 23
Self-citationCurrent and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18
Yao, D., Lai, J., Lu, Y., Zhong, J., Zha, X., Huang, X., Liu, L., Zeng, X., Chen, S., Weng, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1078118 · Cited by 12
Self-citationZahran, A. M., Zahran, Z. A. M., Gamal, D. A., Elsayh, I. K. I., Moeen, S. M., Wahman, M. M., Sabet, M. A., Abdelaal, A. M., Hussein, S., Saad, K., et al. (2023) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2023.35138 · Cited by 10
Lin, Y., Lin, J., Huang, J., Chen, Y., Tan, J., Li, Y., & Chen, S. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.09.01 · Cited by 10
Self-citationHou, Q., Wang, P., Kong, X., Chen, J., Yao, C., Luo, X., Li, Y., Jin, Z., & Wu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1321126 · Cited by 5
Self-citationZhang, Y., Zeng, X., Zha, X., Lai, J., Tan, G., Chen, S., Yu, X., Li, Y., & Xu, L. (2022) · Hematology · doi:10.1080/16078454.2022.2066245 · Cited by 4
Self-citationZhuo, C., Dong, X., Zhao, X., Wu, W., Zhou, H., Feng, J., Liu, L., Feng, M., He, C., & Hou, Y. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101626 · Cited by 3
Taiwo, K. A., Ahmed, I. O., Asafa, M. A., Olarewaju, O. J., Omoyiola, O. A., Oguns, O., Owojuyigbe, T. O., & Bolarinwa, R. A. (2025) · Biomarker Insights · doi:10.1177/11772719251351687 · Cited by 2
Metadata
- Authors
- Yao, D., Xu, L., Tan, J., Zhang, Y., Lu, S., Li, M., Lu, S., Yang, L., Chen, S., Chen, J., Lai, J., Lu, Y., Wu, X., Zha, X., & Li, Y.
- Affiliations
- Jinan University (CN)
- Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, Jinan University, School of Medicine, Jinan University, Guangzhou, China
- Corresponding author
- Yao, Danlin
- Xu, Ling
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-09-16
- Volume
- 8
- Issue
- 47
- Pages
- 81852-81859
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5669853
- OpenAlex
- W2754985307
- Cited by
- 19
- References
- 33
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2020: 4 · 2019: 3 · 2018: 3
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (91642111, S2013020012863, U1301226, 81570143)
- Natural Science Foundation of Guangdong Province (S2013020012863)
- Jinan University
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- chronic myeloid leukemia, tyrosine kinase inhibitors, T cell memory subsets, central memory T cells, stem cell memory T cells, effector memory T cells, naive T cells, CD8+CD28- T cells, immunosuppression, complete remission, T cell homeostasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
